

Corp. Office : 2nd Floor, 'Dorr Oliver' House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai - 400 099.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : gufic@guficbio.com
CIN L65990MH1984PLCO33519

10/LEGAL/NSE/2015-16/GBSL

09th November, 2015

To,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra – Kurla Complex,
Bandra (E), Mumbai – 400051

Symbol: **GUFICBIO**

Dear Sir/Madam,

Sub: un-audited financial result for the quarter and half year ended September 30, 2015

We submit herewith the Un-audited Financial Results for the quarter and half year September 30, 2015. The same have been considered, approved and taken on record at the meeting of the Board of Directors of the company held on November, 09, 2015

Kindly take the above on record.

Thanking You,

Yours truly,
For Gufic Biosciences Limited


Santosh Sharma
Company Secretary




GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2015

Rs. In Lacs

Particulars	Quarter Ended 30.09.2015 Unaudited	Quarter Ended 30.06.2015 Unaudited	Quarter Ended 30.09.2014 Unaudited	Period Ended 30.09.2015 Unaudited	Period Ended 30.09.2014 Unaudited	For the Year Ended 31.03.2015 Audited
INCOME:						
Net Sales / Income from Operations (Net of Excise Duty)	5130.73	3759.20	4263.81	8889.93	8171.87	15142.61
Other Operating Income	10.85	8.40	12.58	19.25	14.64	32.53
Total Income from Operations (Net)	5141.58	3767.60	4276.39	8909.18	8186.50	15175.14
EXPENSES:						
Cost of Materials Consumed	2044.78	1755.99	2262.43	3800.77	3909.38	6579.76
Purchase of Stock-in-Trade	786.09	557.29	272.73	1343.38	826.17	1670.77
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(220.69)	(680.64)	(48.91)	(901.33)	(50.56)	(130.68)
Employee Benefits Expenses	846.15	745.81	457.80	1591.96	825.33	1933.33
Depreciation and Amortisation Expenses	94.56	92.36	103.11	186.92	202.35	385.21
Other Expenses	1240.56	1023.04	907.55	2263.60	1857.44	3675.26
Total Expenses	4791.44	3493.85	3954.71	8285.30	7570.11	14113.66
Profit from Operations before Other Income, finance costs and Exceptional Items	350.14	273.75	321.69	623.88	616.39	1061.48
Other Income	33.36	1.98	(11.88)	35.34	17.36	37.18
Profit from ordinary activities before finance costs and exceptional items	383.50	275.73	309.81	659.22	633.76	1098.66
Finance Costs	122.80	114.73	110.94	237.53	216.78	446.08
Profit from ordinary activities after finance costs but before exceptional items	260.69	161.00	198.87	421.69	416.97	652.59
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	260.69	161.00	198.87	421.69	416.97	652.59
Current Tax	112.20	75.00	103.61	187.20	178.61	278.61
Deferred Tax	(16.60)	(18.03)	(27.65)	(34.63)	(3.91)	(48.84)
Short/(Excess) Tax Provisions of Earlier Years	0.00	0.00	4.43	0.00	4.43	7.08
Net Profit from Ordinary Activities After Tax	165.09	104.03	118.47	269.12	237.84	415.74
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	165.09	104.03	118.47	269.12	237.84	415.74
Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	2205.61	2040.52	1796.92	2205.61	1796.92	1936.49
E.P.S	0.21	0.13	0.15	0.35	0.31	0.54
Public Shareholding						
-- Number of Shares of Rs 1 /- Each	23222355	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding						
a) Pledged / Encumbered						
-- Number of Shares of Rs 1 /- Each	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered						
-- Number of Shares of Rs 1 /- Each	54127645	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%




GUFIC BIOSCIENCES LIMITED

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 30.09.2015

Rs. In Lacs

Particulars	Quarter Ended 30.09.2015 Unaudited	Quarter Ended 30.06.2015 Unaudited	Quarter Ended 30.09.2014 Unaudited	Period Ended 30.09.2015 Unaudited	Period Ended 30.09.2014 Unaudited	For the Year Ended 31.03.2015 Audited
SEGMENT REVENUE						
Sales & Service						
Pharma	5040.12	3650.22	3900.81	8690.34	7455.77	13922.95
Consumer	90.61	108.98	363.00	199.59	716.09	1219.66
Total	5130.73	3759.20	4263.81	8889.93	8171.87	15142.61
Unallocabel Income	44.21	10.38	0.70	54.59	32.00	69.71
Total Segment Revenue	5174.94	3769.58	4264.51	8944.52	8203.87	15212.32
SEGMENT RESULTS						
Pharma	970.22	720.92	760.68	1691.14	1453.88	2701.05
Consumer	10.41	12.04	38.32	22.45	75.62	136.97
TOTAL	980.63	732.96	798.99	1713.59	1529.50	2838.02
Less: Unallocated over heads	502.58	364.87	386.07	867.46	693.39	1354.15
Finance Charges	122.80	114.73	110.94	237.53	216.78	446.08
Depreciation	94.56	92.36	103.11	186.92	202.35	385.21
Tax provision	95.60	56.97	80.40	152.57	179.13	236.85
Net Profit after Tax	165.09	104.03	118.47	269.12	237.84	415.74

UNAUDITED STATEMENT OF ASSETS AND LIABILITIES


(Rs in Lacs)

Particulars	AS AT 30.09.2015 Unaudited	AS AT 30.09.2014 Unaudited	AS AT 31.03.2015 Audited
EQUITY AND LIABILITIES			
Shareholder's Funds			
a) Share Capital	773.50	773.50	773.50
b) Reserves and Surplus	2,205.61	1,796.92	1,936.49
Sub-total - Shareholder's Funds	2979.11	2570.42	2709.99
Non-current liabilities			
a) Long-term borrowings	819.20	1,151.80	1,150.34
b) Deferred tax liabilities (Net)	120.10	159.34	154.73
c) Other long-term liabilities	466.82	163.50	212.27
d) Long-term provisions	147.86	141.90	140.50
Sub-total - Non-current liabilities	1553.98	1616.54	1657.85
Current liabilities			
a) Short-term borrowings	2,707.46	1,604.88	1,790.42
b) Trade payables	5,752.77	5,537.66	4,953.33
c) Other current liabilities	1,586.37	1,466.87	1,301.22
d) Short-term provisions	448.59	370.76	315.97
Sub-total - Current liabilities	10495.19	8980.17	8360.94
TOTAL - EQUITY AND LIABILITIES	15028.28	13167.13	12728.78
ASSETS			
Non-current assets			
a) Fixed assets	2,367.75	2,582.28	2,510.71
b) Non-current investments	0.93	0.92	0.93
c) Long-term loans and advances	804.15	762.03	759.75
d) Other non-current assets	395.89	264.58	282.58
Sub-total - Non-Current assets	3568.72	3609.83	3553.97
Current assets			
a) Current investments			
b) Inventories	4,901.65	3,367.87	3,680.14
c) Trade receivables	4,651.75	4,078.01	3,324.30
d) Cash and cash equivalents	564.62	211.86	620.63
e) Short-term loans and advances	1,341.54	1,899.56	1,549.74
Sub-total - Current assets	11459.56	9557.30	9174.81
TOTAL - ASSETS	15028.28	13167.13	12728.78

Notes forming part of the un-audited financial results for the quarter ended September 30, 2015

1. The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on November 09, 2015.
2. For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2015.
3. Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on September 30, 2015: Nil.
4. Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board
Gulf Biosciences Limited


Pranav Choksi
Executive Director



Mumbai dated November 09, 2015